Centre awarded £10 million grant from Department for International Development UK
The grant, together with on-going financial support from GlaxoSmithKline (GSK), is to enable endemic countries to reduce the prevalence of LF (and other related NTDs) and make progress towards LF elimination. The Centre's goals will be achieved through four main projects:
Mass Drug Administration
Twelve countries (Bangladesh, Burkina Faso, DRC, Ghana, Guinea, Ethiopia, Liberia, Malawi, Mozaimbique, Nepal, Tanzania, Zambia) will receive support to implement or continue the implementation of MDA to eliminate LF by 2020
Capacity Building
Six countries (Egypt, Kenya, Malawi, Ghana, Sierra Leone, Sri Lanka) will receive support to strenghten and operate laboratories.
Operational Research
Projects will be undertaken to support the evidence base for the elimination strategy and apply tools for assessing progress.
Partnership Relations
Successful global partnership will be achieved by advocacy, communication, resource mobilisation and co-ordination.
If you would like to read the Centre's press release please click here.
